Xoma Royalty Corporation · NASDAQ:XOMA
Xoma Royalty — Investor Presentation (January 2026)
10 slides from Xoma Royalty's investor presentation, January 2026
Slide 1: Corporate Presentation: The Royalty Aggregator for Biotech Companies
CORPORATE PRESENTATION THE ROYALTY NASDAQ COMMON: XOMA AGGREGATOR NASDAQ PERPETUAL PREFERRED SHARES: XOMAP, XOMAO FOR BIOTECH COMPANIES JANUARY 2026
Slide 2: Disclaimers
DISCLAIMERS Certain statements in this presentation are forward-looking statements XOMA Royalty’s views only as of the date of this presentation and within the meaning of Section 27A of the Securities Act of 1933 and should not be relied upon as representing its views as of any Section 21E of the Se
Slide 3: XOMA Royalty – What We Do
XOMA ROYALTY – WHAT WE DO Royalties Science Milestones Structuring The Biotech Royalty Aggregator 3
Slide 4: Royalty Snapshot: Current Capitalization
XOMA ROYALTY SNAPSHOT: Current Capitalization $27.21 / SHARE (1) 18.6M SHARES (FULLY DILUTED TREASURY METHOD) $506M MARKET CAP (FULLY DILUTED) ~$598M $65M PERPETUAL PREFERREDS ENTERPRISE $112M ROYALTY BACKED LOAN VALUE $85M CASH (2) (1) Share price as of market close 01/07/2026 (2) Cash available to
Slide 5: XOMA Royalty Is Differentiated
XOMA ROYALTY IS DIFFERENTIATED Capital per transaction $200M+ Royalty Pharma $200M – $100M DRI Healthcare Trust $100M – FOCUSED ON Ligand HCRx $25M EARLY- to MID-STAGE CLINICAL ASSETS <$25M PRECLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVAL COMMERCIAL 5
Slide 6: XOMA Royalty's Business Model: The Compounding Effect
XOMA ROYALTY’S BUSINESS MODEL: Path to Sustained THE COMPOUNDING Profitability EFFECT GROWING # of ROYALTIES ↑ CASH RECEIPTS LOW EXPENSES LOW SHARE COUNT INFLECTION HIGH EPS POINT LOW EXPENSES SIGNIFICANT SHARE PRICE APPRECIATION 2023 future 6
Slide 7: Royalty's Business Model Differentiation Should Enhance Value Creation
XOMA ROYALTY’S BUSINESS MODEL DIFFERENTIATION SHOULD ENHANCE VALUE CREATION Visibility into future DCF VALUE + PIPELINE royalty portfolio DCF differentiates VALUE VALUE XOMA ROYALTY from majority of royalty competitors TIME 7
Slide 8: 2025 Year in Review: Reputation Inflection
2025 YEAR IN REVIEW: REPUTATION INFLECTION The TRINITY: Assets / Tax Benefits / Cash J A N 2 0 2 5 A P R 2 0 2 5 M A Y 2 0 2 5 J U L 2 0 2 5 ADDITIONAL +24 R O Y A L T Y + O U T L I C E N S I N G R O Y A L T Y A C Q U I S I T I O N 1 D-Fi Royalty, Warrants Sale of All Pipeline Assets Mezagitamab Roy
Slide 9: Building the Long-Term XOMA Royalty Business
BUILDING THE LONG-TERM XOMA ROYALTY BUSINESS >100 Assets seralutinib (PAH/PH-ILD) (1L pLGG) ersodetug (THI) mezagitamab (ITP/IgAN) >$140M volixibat (PBC/PSC) (1) osavampator (MDD) milestones received OHB-607 (BPD) since 2017 rilvegostomig (cancer) UNDISCLOSED Anti-TL1A (UC/Crohn’s) >$2B (2) in futur
Slide 10: Key Portfolio Events Anticipated in 2026
KEY PORTFOLIO EVENTS ANTICIPATED IN 2026 COMMERCIAL REGULATORY SALES RAMPS EMA DECISION REGULATORY GUIDANCE + BUSINESS DEVELOPMENT ERSODETUG ( R E Z O L U T E ) REC-4881 ( R E C U R S I O N P H A R M A ) DATA ANNOUNCEMENTS PHASE 3 PHASE 3 PHASE 2 PRODUCT LAUNCH SERALUTINIB ERSODETUG RILVEGOSTOMIG PU